These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37366218)

  • 1. Parkinson's disease - current treatment.
    Wang R; Shih LC
    Curr Opin Neurol; 2023 Aug; 36(4):302-308. PubMed ID: 37366218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.
    Di Luca DG; Reyes NGD; Fox SH
    Drugs; 2022 Jul; 82(10):1027-1053. PubMed ID: 35841520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New dopaminergic therapies for PD motor complications.
    Larson D; Simuni T
    Neuropharmacology; 2022 Feb; 204():108869. PubMed ID: 34742740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On demand therapy for Parkinson's disease patients: Opportunities and choices.
    Hauser RA; LeWitt PA; Comella CL
    Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Parkinson's disease in the advanced stage.
    Ossig C; Reichmann H
    J Neural Transm (Vienna); 2013 Apr; 120(4):523-9. PubMed ID: 23474822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-related wearing-off in Parkinson's disease: identification and management.
    Pahwa R; Lyons KE
    Curr Med Res Opin; 2009 Apr; 25(4):841-9. PubMed ID: 19228103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
    Antonini A; Nitu B
    J Neural Transm (Vienna); 2018 Aug; 125(8):1131-1135. PubMed ID: 30006821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
    Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
    Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.
    Müller T; Russ H
    Expert Opin Pharmacother; 2006 Sep; 7(13):1715-30. PubMed ID: 16925499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic and pharmacologic perspectives in Parkinson's disease].
    Corvol JC; Mariani LL
    Rev Prat; 2018 May; 68(5):515-519. PubMed ID: 30869416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa in Parkinson's disease: from the past to the future.
    Pezzoli G; Zini M
    Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
    Clarke CE; Worth P; Grosset D; Stewart D
    Parkinsonism Relat Disord; 2009 Dec; 15(10):728-41. PubMed ID: 19805000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varying time-course of effects of high frequency stimulation of sub-regions of the globus pallidus in patients with parkinson's disease.
    Angeli A; Akram H; Zacharia A; Limousin P; Hariz M; Zrinzo L; Foltynie T
    Parkinsonism Relat Disord; 2015 Jun; 21(6):597-602. PubMed ID: 25842261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's Disease.
    Reich SG; Savitt JM
    Med Clin North Am; 2019 Mar; 103(2):337-350. PubMed ID: 30704685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.